A&D Pharma Hldgs N.V


A&D Pharma Hldgs N.V


Bucharest, Romania - 28 August 2008 - A&D Pharma Holdings N.V. (the "Group", the
"Company" or "A&D Pharma"), the Dutch holding company that owns the largest
integrated pharmaceutical sales and marketing services, wholesale and retail
business in Romania, announces that Mr. Dragos Dinu is stepping down from his
position as Chief Executive Officer ("CEO") and Executive Director of the Group.
Mr. Dinu will continue to contribute to the Group's development in a consultancy
role until the end of this year. A&D Pharma also announces the appointment of
Mr. Dimitris Sophocleous as Chief Financial Officer ("CFO") and Executive
Director to succeed Mr. Roger de Bazelaire, the Group's current CFO, who is
stepping down from the Board by mutual consent with immediate effect.


The Board is reviewing candidates to replace Mr. Dinu as CEO, and the
appointment of a successor will be announced in due course when the selection
process has been completed. In the meanwhile, Mr. Robert Popescu, Chief
Operating Officer ("COO") of the Wholesale Business has been appointed as
Interim CEO. He will chair the Executive Committee until the appointment of the
new CEO and continue to lead the Wholesale business line. Vivian Diaconescu and
Claudiu Opran, the current Chief Operating Officers of the Sales & Marketing and
Retail businesses will also continue to lead their respective business lines.

On behalf of the Board of Directors, Dr. David Ebsworth, Chairman of A&D Pharma,
commented: "The mission of A&D Pharma is to create value for all its consumers,
shareholders, investors, business partners, employees and the wider community.
In the interest of all, we believe that the time has come for A&D Pharma to take
new measures to accelerate its development and deliver on its strategic goals.
The Company is entering a new development stage, with a renewed focus on
profitable growth, increasing its flexibility to take advantage of opportunities
available in a competitive and fast changing market.

"The Board of Directors thanks Dragos Dinu for his leadership and contribution
to the success of A&D Pharma over the past 13 years. His dedication and hard
work have been instrumental in shaping A&D Pharma into the largest integrated
pharmaceutical business in Romania. We wish Dragos well in his future business
endeavours and will continue to benefit from his advice and expertise in his
consultant role."

Mr. Dragos Dinu declared that "A&D Pharma has a strong history in driving
innovation and viable change and has proven that it possessed a solid business
in all stages of its development. Looking back, I can say that the Company has
outperformed the expectations that we as a management team had at the beginning.
Looking forward I am confident that the management and employees of A&D Pharma
will continue to set high standards and expectations and deliver on them. They
have the capacity to do it."


The Board of A&D Pharma is pleased to announce the appointment of Mr. Dimitris
Sophocleous as CFO of the Group with immediate effect. Mr. Sophocleous was
previously at Romtelecom, Romania's incumbent fixed telephony operator, where he
was CFO from 2004 to 2007. Before that, he was CFO of Cosmorom, one of Romania's
largest mobile operators, from 2001 to 2004 and partly owned by the OTE Group
(Hellenic Telecommunication Organisation).

Dr. David Ebsworth commented: "The Board of Directors welcomes Dimitris
Sophocleous to A&D Pharma. He has a strong track record managing the finances of
large companies in Romania and all the skills required to manage A&D Pharma's
finances efficiently. The Board thanks Roger de Bazelaire for his contributions
to the Company since joining and wishes him every success in the future."

For further information, please visit www.adpharma.ro or contact:

A&D Pharma                                    A&D Pharma
Investor Relations                            Romanian Press Relations
Cristian Barbulescu                           Diana Klusch
Tel: +40 21 301 7474                          Tel: +40 728 188 146
[email protected]               [email protected]

Shared Value Limited
Investor & Media Relations
Nicolas Duperrier
Tel. +44 (0)20 7321 5010
[email protected]


A&D Pharma Holdings N.V. is the Dutch holding company of A&D Pharma Holdings
S.R.L., the leading pharmaceutical sales and marketing services, wholesale and
retail business in Romania. Founded in 1994, the Group owns Romania's leading
pharmaceutical wholesale, sales and marketing services for CHC and Rx products
network "Mediplus", and Romania's largest national branded chain of pharmacies

The Group's consolidated sales increased at a compound annual rate of 45%
between 2003 and 2007, amounting to EUR 425 million for the twelve months ended
31 December 2007. A&D Pharma's shares have been traded in the form of Global
Depositary Receipts ("GDRs") on the regulated market of the London Stock
Exchange since October 2006 under the symbol 'ADPH'.

This release is not an offer for sale of the GDRs of A&D Pharma, or any other of
its securities, in the United States or in any jurisdiction where any offer,
sale or solicitation in respect of such securities is not permitted. Securities
may not be offered or sold in the United States absent registration or an
exemption from registration under the US Securities Act of 1933, as amended, or
in any jurisdiction where such offer or sale is not permitted.

Certain statements made in this release are forward looking statements. Such
statements are based on current expectations and are subject to a number of
risks and uncertainties that could cause actual events or results to differ
materially from any expected future events or results referred to in these
forward looking statements.

This release should not be construed as the giving of advice or the making of a
recommendation and should not be relied on as a basis for any decision or
action. In particular, actual results and developments may be materially
different from any forecast, opinion or expectation expressed in this
presentation and the past performance of the price of securities must not be
relied upon as a guide to their future performance.